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Abstract
Introduction The causes of relapse in patients with Cro-
hn’s disease (CD) and ulcerative colitis (UC) are largely
unknown. This paper reviews the epidemiological and
clinical data on how medications (non-steroidal anti-
inflammatory drugs, estrogens and antibiotics), lifestyle
factors (smoking, psychological stress, diet and air pollu-
tion) may precipitate clinical relapses and recurrence.
Potential biological mechanisms include: increasing
thrombotic tendency, imbalances in prostaglandin synthe-
sis, alterations in the composition of gut microbiota, and
mucosal damage causing increased permeability.
Results The clinical epidemiological data consistently
reports positive associations between smoking and relapses
in CD, and inverse ones with UC. For NSAIDs and
estrogens, the epidemiological findings are inconsistent,
although general antibiotic use was associated with a
reduced risk of relapse in CD. High levels of stress were
positively associated with relapse, although psychological
interventions did not have therapeutic benefits. The limited
work on diet has reported sulphur-containing foods are
positively associated with relapse in UC, but there is no
work in CD. Ecological data reported positive correlations
between air pollution levels and IBD hospitalisations.
Conclusions In the future, to clarify this area, more
clinical epidemiological work is required where detailed
drug types and doses, and complete dietary intakes are
measured, in specific forms of IBD. Such work could
provide guidance to both patients and doctors to help
maintain remission.
Keywords Relapse  Recurrence  Inflammatory bowel
disease  Precipitating factors
Introduction
The inflammatory bowel diseases (IBD) are a heteroge-
neous group of disorders affecting the gastrointestinal tract,
of which the commonest are Crohn’s disease (CD) and
ulcerative colitis (UC). The prevalence of IBD in Western
countries has increased in the last 50 years and, although
the etiology is largely unknown, probably involves a
complex interaction between genetic, immunological and
environmental factors, which culminates in an aberrant
response to luminal antigens [1]. Although genetic loci
have been found for predicting the nature of the disease [2],
the rapid increase in the prevalence of IBD suggests that
environmental factors are responsible. Patients with IBD
have an impaired quality of life [3, 4]; require lifelong
treatments, including medications and surgery [5]; have an
increased risk of colorectal carcinoma [6] and may suffer
from extra-intestinal complications [7, 8]. Clinically, IBD
has a relapsing and remitting course, so the aims of therapy
are to both induce and maintain remission. Exacerbating
factors which precipitate clinical relapses should therefore
be avoided, but currently these are poorly understood.
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This article reviews the evidence on whether certain
environmental factors influence the development of clinical
relapses and recurrences (further disease postsurgery). These
include the medications: nonsteroidal anti-inflammatory
drugs, estrogens and antibiotics; and aspects of lifestyles:
smoking, alcohol, stress, air pollution and diet. Plausibly,
there may be interactions between these exposures, possibly
through interaction with the microbiota which may alter the
disease course. Clarifying whether these exposures are
involved is important in attempts to reduce relapse rates and
improve clinical outcomes and patients’ quality of life. This
paper will discuss possible biological mechanisms on how
each of these factors may influence clinical outcomes and
whether these mechanisms are supported by the clinical and
epidemiological studies (summarized in Table 1).
Known Clinical Factors for Relapse
The relapse rate in IBD is currently difficult to predict in
individual patients. However, certain clinicopathological
features are associated with both a worse prognosis and a
more severe disease course. Patients younger than 40 years
at diagnosis are more likely to have a severe CD course [9].
Furthermore, this also applies to those requiring either
steroids at their first presentation, two or more courses of
steroids annually, patients with perianal involvement and
those with penetrating/stricturing complications [9–11].
For UC, younger patients, those with multiple relapses and
patients with basal plasmocytosis in histological biopsies
are more likely to relapse [12].
Smoking
Chemicals in cigarette smoke have pathophysiological
effects on the vasculature which affect vessel patency,
vascular tone, inflammatory activity and thrombotic ten-
dency. Smoking decreases both nitric oxide synthesis and
endothelium-dependent vasodilatation resulting in vessel
narrowing and a pro-thrombotic, pro-inflammatory state,
which is reversible upon cessation [13–15]. This throm-
botic tendency is exacerbated by smoking which increases
platelet adhesion and aggregation [16]. Such a role of
thrombosis seems plausible as individuals with an inborn
error of coagulation, such as hemophilia, have a lower
incidence of CD [17]. The pathogenesis of CD is a complex
multistaged process not yet fully understood, although
thrombosis may be involved through a process initiated by
focal arteritis. The latter leads to fibrin-deposition, arterial
occlusion, and subsequent microinfarction or neovascu-
larization [18]. This possible mechanism is supported by
both experimental work, which demonstrated thrombosis in
capillaries of rectal biopsies of patients with UC and CD
[19]. Furthermore, angiographic studies have reported
reduced density and caliber of vessels resulting in a lower
mesenteric blood flow in segments of affected bowel [20,
21]. Whether these pathological changes are directly
involved in the pathogenesis of CD, or are a secondary
consequence, is unknown. Thrombotic events leading to
downstream ischemia and the production of reactive oxy-
gen species [22] may exacerbate CD firstly by causing the
inducible transcription factor NF-jB (nuclear factor jB) to
bind to DNA [23]. This promotes inflammation mediated
through up-regulating cytokines and chemokines [24, 25].
Previous studies have identified activated NF-jB in the
epithelial cells of patients with IBD [26]. Secondly, reac-
tive oxygen species may also precipitate relapses by
increasing the permeability of the mucosal and vascular
epithelium, mediated through superoxide and hydrogen
peroxide [22, 27]. This increased permeability may lead to
a greater exposure of antigens exacerbating CD.
The experimental mechanisms for how smoking may
precipitate clinical relapse of CD are supported by the epi-
demiological data. A meta-analysis of 16 observational
studies of 2,962 CD patients (48 % smokers) reported that
smokers were more likely to develop clinical recurrence after
disease-modifying surgery than non-smokers (OR 2.07, 95 %
CI 1.25–3.44, p \ 0.005) [28]. A retrospective cohort study
in France of 400 patients with CD reported that smokers were
more likely to require glucocorticoids and immunosuppres-
sive therapy—markers of disease severity—during follow-up
[29]. For patients smoking between 10 and 20 cigarettes per
day, there was a greater risk of requiring glucocorticoids (RR
1.15, 95 % CI 1.05–1.25) and immunosuppressive therapy
(RR 1.58, 95 % CI 1.09–2.29). A prospective cohort study,
nested in the placebo arm of a Canadian multicenter ran-
domized controlled trial, studied 152 CD patients. In total,
40 % relapsed, which was significantly higher in smokers
(HR 2.1, 95 % CI 1.1–4.2) [30]. A cohort study of 622 French
patients with CD reported that smokers (of greater than 16
cigarettes per day) were more likely to relapse (adjusted RR
1.35, 95 % CI 1.03–1.76, p = 0.03) [31]. There was evi-
dence of a dose–response, which has been reported in other
work in both relapse and recurrence [32–35].
For UC, a number of investigations have documented that
perhaps, surprisingly, smoking is inversely associated with
disease severity. A French cohort study of 96 patients
reported that, following smoking cessation, there was a sta-
tistically significant increase (p \ 0.01) in years with active
disease, years of hospitalization and years with medical
therapy (oral steroids, IV steroids and azathioprine) [36]. An
Australian prospective cohort study of 101 UC patients, all
with a functioning ileal pouch-anal anastomosis, were fol-
lowed up for 2 years, during which time non-smokers were
more likely to develop episodes of pouchitis than smokers,
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although this did not quite reach statistical significance (25
vs. 6 %, p = 0.054) [37]. The mean number of episodes of
pouchitis per group over follow-up of approximately
3.5 years was higher in non-smokers compared to smokers
(0.639 vs. 0.059, p = 0.005, range of number of epi-
sodes = 0–6). Why smoking may prevent relapse of UC is
uncertain, but nicotine does decrease the expression of pro-
inflammatory cytokines, such as IL-1b and IL-8 [38],
increase anti-inflammatory ones, such as IL-4 [39], and
modulates the innate immune response through a Toll-like
receptor-4-dependent pathway [40].
In summary, the biological mechanisms for why
smoking may affect CD and UC in opposing ways are
unknown. Tobacco smoke contains approximately 3 500
compounds [41], some of which may have multiple effects
on intestinal mucosal cells. However, the consistent data
from both experimental and epidemiological studies,
including the dose–response effects, suggest smoking is a
causative factor for CD relapse. The inverse association
with UC requires clarification by understanding the possi-
ble underlying mechanisms. However, smoking cessation
should be encouraged in all IBD patients for its general
health benefits, but particularly in those with CD.
NSAIDs
There are plausible biological mechanisms for how non-
steroidal anti-inflammatory drugs (NSAIDs), including
Table 1 Summary of potential exposures for relapse
Exposure State of the evidence What needs to be done?
Smoking Plausible biological
mechanisms including
decreased blood vessel
patency and increased
thrombotic tendency.
Clinical data report that
smoking increases the
risk of relapses of CD,
but reduces that of UC
Clarify the underlying
biological mechanisms
to support the
consistent
observational data
NSAIDs Plausible biological
mechanisms involving
increased intestinal
permeability and
altered production.
Conflicting
epidemiological data
reporting positive or no
associations
Cohort studies
comparing relapse rates
in patients with IBD
according to prior
NSAID use, adjusting
for all covariates,
including maintenance
therapies
Estrogen-
containing
medications
Possible effects in
increasing the
thrombotic tendency.
For the OCP, studies
document positive, or
no, associations. For
HRT, data showing
inverse or no
associations
Detailed prospective
studies of patients
investigating CD and
UC individually, the
varying clinical
scenarios and the dose
and duration of
estrogen use
Antibiotics Plausible mechanisms
involving antibiotics
inducing changes in the
proportions of
pathogenic and
commensal gut
bacteria.
Epidemiological work
for CD documenting
inverse associations
between general
antibiotic use and
relapse, but not for UC
Clarification of the
mechanisms of
individual
microorganisms in the
pathogenesis of
relapse. Prospective
cohort studies
measuring antibiotics,
including their dose
and duration of use for
different clinical
manifestations of IBD.
Importantly,
consistency is required
between the
mechanistic and
epidemiological data
Stress Mechanisms unknown,
although possible
effects on decreasing
mucous secretion and
increasing gut
permeability. Most
observational work
shows positive
associations between
stress and relapse, but
no proven beneficial
psychological
interventions
Assessment of
psychological
interventions, in
randomized controlled
clinical trials, to lower
stress and reduce
relapse rates
Table 1 continued
Exposure State of the evidence What needs to be done?
Diet Laboratory and
observational work that
excess dietary sulfur
may precipitate relapse
Detailed cohort studies in
patients with IBD
recording their dietary
intake and correlating
with clinical relapse.
Randomized controlled
clinical trials of dietary
interventions, including
a low-sulfur diet in UC
Pollution Laboratory work reports
detrimental effects of
air pollutants on the
intestinal mucosa.
Ecological work
reporting associations
with density of air
pollutants and IBD
hospitalizations
Analytical
epidemiological studies
comparing exposure to
pollutants and risk of
clinical relapse
IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative
colitis, NSAID nonsteroidal anti-inflammatory drugs, HRT hormone
replacement therapy
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aspirin, may exacerbate inflammatory bowel disease [42].
NSAIDs enter the hydrophobic channel of cyclooxygenase
enzymes (COX) and form a hydrogen bond with arginine
[43, 44], whereas aspirin irreversibly binds to a serine
residue [45]. Consequently, there is steric blockage of the
COX channel preventing the n-6 polyunsaturated fatty acid
arachidonic acid entering [45]. Subsequently, prostaglandin
production from arachidonic acid is reduced, including
prostacyclin (PGI2), prostaglandin E2 and thromboxane
(TXA2) [46]. Prostaglandin E2 (PGE2) has anti-inflamma-
tory effects mediated by inhibiting TNF-a, IL-1, 5-lipo-
oxygenase and leukotrienes [47, 48]. Plausibly, decreasing
PGE2 levels by NSAID use may have pro-inflammatory
consequences. Secondly, NSAIDs increase the permeabil-
ity of cell membranes by interacting with and disrupting
phospholipids [49]. This may result in an increased expo-
sure to luminal antigens, the recognition and processing of
which are disturbed in IBD [2, 50]. Finally, NSAIDs may
decrease COX-mediated vasorelaxation within the gastro-
intestinal vasculature resulting in impaired healing and
exacerbating inflammation [51].
The findings from epidemiological studies investigating
relapse and NSAID use are conflicting. The ideal study
design would compare relapse rates in patients with IBD
according to NSAID use or not. To the best of our
knowledge, there is only one such study: A retrospective
investigation of 60 patients treated in a tertiary referral
center (68 % CD, 20 % UC and 12 % indeterminate coli-
tis) which reported that patients were more likely to be
taking a daily dose of any NSAIDs the month before
relapse than those with IBD who were not (adjusted OR
6.31, 95 % CI 1.16–34.38, p = 0.03) [52]. The analysis
was performed with CD and UC as a combined group and
importantly neither smoking status, maintenance therapy
nor compliance were included due to incomplete data
collection. A case–control study of 60 IBD in-patients (36
CD and 24 UC) from the USA, which used irritable bowel
syndrome patients as the control group, also reported
NSAIDs were positively associated with relapse (OR 20.3,
95 % CI 2.6–159.7, p \ 0.0001) [53]. A Scottish study of
200 IBD patients compared with general population con-
trols found no association between current NSAID use and
emergency admissions for IBD colitis (CD: OR 1.12, 95 %
CI 0.48–2.59; UC: OR 1.72, 95 % CI 0.62–4.79) [54]. A
retrospective record review of 192 IBD patients (58 % CD)
in a US hospital reported no association for relapses of CD
(OR 0.34, 95 % CI 0.07–1.39, p = 0.16) or UC (OR 0.65,
95 % CI 0.15–3.31, p = 0.50) [55]. A retrospective cohort
study used a computerized record system of 1940 IBD
patients (45 % CD) registered in one US health mainte-
nance organization, with follow-up for at least 6 months,
and reported no association between NSAID use and IBD
relapse (HR 0.93, 95 % CI 0.68–1.27) [56].
In summary, the laboratory data suggest several mech-
anisms for NSAIDs inducing relapses, with some sup-
portive, but not consistent, clinical epidemiological data.
Further work is required investigating NSAID use specifi-
cally in CD and UC patients with and without clinical
relapses, adjusting for all covariates and with detailed
information on the prescription of maintenance therapies.
However, the current evidence would suggest using
NSAIDs with caution in IBD patients, and the guidance
from the British Society of Gastroenterology (BSG) rec-
ommends this approach [57].
Estrogen-Containing Medications
Medications containing estrogen include the oral contra-
ceptive pill (OCP) and hormone replacement therapy
(HRT). In UK, it is estimated that 28 % of women younger
than 50 years use the OCP [58]. HRT was used by
approximately 20 million women worldwide in the late
1990s [59]. Estrogens are generally safe medications,
although they may cause the uncommon, but serious side
effect of venous thromboembolism (VTE) [60]. The hor-
mone increases the activity of clotting factors of both the
intrinsic and extrinsic pathways, and raises fibrinogen
concentrations, which predisposes to thrombosis [61].
Therefore, it is likely that estrogens may precipitate
relapses and recurrences of CD due to similar mechanisms
to those described for smoking. Estrogens, which increase
thrombogenicity, may plausibly promote microinfarction,
thus contributing to the downstream effects of ischemia,
exacerbating inflammation, and therefore clinical relapses.
Estrogen receptors are present in the human colon [62, 63],
although their physiological role, and whether they are
involved in the pathogenesis of IBD is unknown.
The results of clinical epidemiological studies investi-
gating estrogen use and relapse are conflicting. A pro-
spective cohort study from Paris followed 331 women with
a Crohn’s disease activity index of less than 200 at
enrollment for 12–18 months [64]. At baseline, oral con-
traceptive users (10 % using the progesterone-only pill)
were more likely to have active colonic disease than non-
users (59 vs. 47 %, p = 0.03), but there were no sub-
sequent associations between the OCP and relapses during
follow-up (HR 1.11, 95 % CI 0.80–1.55). A further pro-
spective investigation, nested in the placebo arm of a
randomized controlled trial [30], followed 152 CD patients
(52 % female), many of whom were eligible to take the
OCP for up to 48 weeks. Current and previous OCP users
were significantly more likely to relapse than nonusers (HR
3.0, 95 % CI 1.5–5.9, p \ 0.001). In a study of 97 women
who underwent primary surgical resection for CD, the
recurrence rates at 5 and 10 years were compared between
Dig Dis Sci
123
participants who were users and nonusers of the OCP in the
year following surgery [65]. There were no statistically
significant differences at both 5 years (25 vs. 28.4 %) and
10 years (40.7 vs. 64.0 %). The small number of patients
studied, particularly at 10 years, would have made true
differences hard to detect. The effect of estrogens on UC
relapse was investigated in a prospective cohort study in
the USA and Canada in 74 participants (57 % women)
taking the OCP, but reported no statistically significant
difference in relapse rates between users and nonusers
(26.5 vs. 40 %) [12].
HRT use was investigated in a US case–control of 65
postmenopausal women with CD (n = 40) and UC
(n = 25) and reported an inverse association with disease
activity in IBD as a whole (HR 0.18, 95 % CI 0.04–0.72,
p = 0.001) [66]. More than 1 year’s use of HRT was
associated with a greater reduction in relapse than use for
just 1 year. A prospective record review of 192 IBD
patients (58 % CD), seen by a single gastroenterologist,
detailed information on HRT use (obtained from a general
information chart) [55]. Relapse of IBD was recorded, and
there were no associations with either CD (OR 0.34, 95 %
CI 0.07–1.39) or UC (OR 1.00, 95 % CI 0.16–7.63).
In summary, differences in the results of epidemiologi-
cal studies investigating exogenous estrogen imply its
influence on IBD is unknown. These inconsistencies may
be explained by the differences in patient ages, the type of
disease and the doses of estrogen studied. Further detailed
clinical epidemiological observational studies documenting
the precise clinical scenarios and estrogen preparations are
required to clarify whether estrogens do precipitate relap-
ses and recurrences.
Antibiotics
The human gastrointestinal system contains approximately
100 trillion (1014) microorganisms, predominantly in the
colon, consisting mainly of species of Streptococci,
Staphylococci and Lactobacilli [67]. Indeed, the com-
monest locations for IBD, the terminal ileum and colon
[67], contain bacteria which influence fermentation and
immunoregulation [68, 69]. The use of antibiotics, which
affect the composition of the gut microbiota, may therefore
influence clinical disease activity if there is an imbalance
between commensal and/or potentially pathogenic bacteria.
A role for bacteria is supported by the association between
CD and mutations of the NOD2/CARD15 gene, which is
involved in the immunological response to bacteria [70].
Antibiotics could plausibly increase or decrease the risk of
relapse according to the way they influence the composi-
tion of the microbiota. Demonstrating antibiotics affect
relapse would be supported by, firstly, beneficial evidence
for antibiotics as a treatment for IBD and, secondly,
investigating whether antibiotics used for other indications
influence relapse and recurrence.
For antibiotic use for non-IBD indications, an epide-
miological case-crossover study of 3,435 UK participants
(35 % CD) in the UK General Practice Research Database
reported an inverse association for use of any antibiotics
prescribed 60 days before relapse in CD (OR 0.78, 95 %
CI 0.64–0.96, p \ 0.019), but not UC (OR 0.96, 95 % CI
0.82–1.12, p = 0.58) [71]. There was also a significant
effect of the timing of antibiotics, with participants pre-
scribed antibiotics 0–15 days before relapse least likely to
relapse (OR 0.60, 95 % CI 0.43–0.83, test for trend,
p = 0.001). The treatment of moderately active IBD with
antibiotics was documented in a systematic review and
meta-analysis of 23 RCTs (14 CD) in adults [72]. This
compared the effectiveness of numerous singular and
combination antibiotic regimens versus placebo for
inducing remission. For CD, 1,160 patients were treated for
between 4 and 16 weeks with antibiotics to induce remis-
sion, and a beneficial effect was reported both for inducing
remission (RR 0.85, 95 % CI 0.73–0.99, p = 0.03) and in a
sub-cohort of 186 patients for maintaining remission (RR
0.62, 95 % CI 0.46–0.84, p = 0.002). For UC, 662 patients
were treated for between 1 and 12 weeks, and a beneficial
effect was observed (RR 0.64, 95 % CI 0.43–0.96,
p = 0.03). A diverse number of antibiotics were studied
including anti-tuberculosis drugs, macrolides, fluoroquin-
olones, 5-nitroimidazoles and rifaximin, either alone or in
combination.
In summary, antibiotic therapy in active IBD may have
clinically beneficial effects, although epidemiologically;
the type of antibiotic, dose and clinical setting needs to be
clarified. Currently, antibiotics have therapeutic uses in
IBD for the treatment of complications [57]. More studies
are required in different populations to see whether general
antibiotic use affects relapse, which may subsequently
inform prescribing practice in IBD patients.
Stress
Stress may be defined as ‘‘a threat to homeostasis’’ [73],
provoked by stressors [74], which may be either physical or
psychological [74]. Stressors initiate both central and
peripheral responses to alleviate the ‘‘threat’’ and maintain
homeostasis through behavioral and physical adaptations
[75]. In rats with quiescent colonic inflammation, disease
re-activation occurred after restrainment [76], and in
murine work, stress reduced mucous secretion and
increased colonic permeability [77], both features of IBD.
The consequences of stress can be investigated in either
follow-up observational work, or randomized controlled
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trials of psychological interventions designed to alleviate
stress. A Canadian observational cohort study recruited 101
CD patients in clinical remission with follow-up for 1 year
[78]. At baseline, and 3-month intervals, psychosocial
questionnaires measuring stress, psychosocial distress and
coping strategies were administered. Relapse was posi-
tively associated with both stress (HR 4.5, 95 % CI
1.9–10.7, p \ 0.001) and coping strategies (HR 1.9, 95 %
CI 1.2–2.8, p = 0.004) measured using a validated tool. A
prospective cohort study of 62 Italian UC patients moni-
tored symptoms at 6-month intervals [79], in participants
completing a perceived stress and depression question-
naire. Patients in the highest tertile of perceived stress were
more likely to relapse (OR 6.5, 95 % CI 1.2–34, p \ 0.05),
although there were no associations with depression. In
Canada, 704 patients with known IBD (61 % CD) were
sent surveys at 3-month intervals, for 1 year to measure
disease activity, perceived stress and exposure to ‘‘major
life events’’ [80]. High perceived stress levels were asso-
ciated with increased exacerbations (OR 2.40, 95 % CI
1.35–4.26), but not major life events. In a further pro-
spective investigation of 85 consecutive IBD patients,
participants completed monthly questionnaires, of which
32 patients (75 % CD) relapsed [81]. There were no sig-
nificant associations reported between stress levels and the
risk of relapse and non-relapse (47 vs. 50 %, p = NS).
A Cochrane review of 21 psychological studies (1,745
participants) assessed interventions in IBD and reported no
difference in remission rates between the intervention and
the control groups at 12 months (OR 0.85, 95 % CI
0.48–1.48) [82]. In a European multicentered randomized
controlled trial of 114 IBD patients (49 % CD) who had
relapsed, or had ‘‘enduring disease’’ in the last 18 months,
participants were randomized to receive either ‘‘treatment
as usual,’’ or stress management psychotherapy [83]. There
were no statistically significant differences between relapse
rates during the course of the study between groups (23 vs.
30 %, p [ 0.05). Therefore, most evidence suggests asso-
ciations between higher stress levels and clinical relapses,
although to date there are no psychological interventions to
prevent these.
Diet
Dietary factors may influence relapse, as the pathophysi-
ology of IBD may be an exaggerated reaction to luminal
antigens. In pediatric CD patients, enteral diets, both ele-
mental and polymeric [84, 85], are used to induce remis-
sion, although symptoms do recur when patients restart
their normal diet [86]. Food contains a combination of
macro- and micronutrients (including vitamins and miner-
als), and many food additives. Although there is evidence
that diet may affect the development of new IBD, there is
minimal work on food items that may precipitate relapse.
One mineral for which there are plausible biological
mechanisms for inducing relapse is sulfur. Dietary sulfur is
present as sulfated amino acids, inorganic sulfur and a
preservative food additive [87, 88]. Sulfur may be toxic to
human colonocytes following its metabolism by colonic
bacteria to hydrogen sulfide (H2S) [89]. This mechanism
was demonstrated in the colonocytes of anaesthetized rats
which were perfused with either H2S or control buffer. In
the former, there was superficial mucosal ulceration, dose-
dependent apoptosis, and loss or shrinkage of goblet cells
and crypts [89, 90]. Furthermore, sulfides inhibited the
butyrate-dependent energy metabolism of colonocytes
[91], which may have a pathophysiological effect on such
cells. In a clinical study investigating dietary sulfur, a UK
prospective cohort of 183 UC patients in remission com-
pleted weekly food frequency questionnaires [92]. The
authors derived an index of sulfur intake using information
from the Royal Society of Chemistry food classification.
The highest tertile of total dietary sulfur intake was posi-
tively associated with relapse (OR 2.76, 95 % CI
1.19–6.40), as was sulfate (OR 2.61, 95 % CI 1.08–6.30).
A high consumption of red and processed meat was posi-
tively associated with relapse (OR 5.19, 95 % CI
2.09–12.9), and meat protein is an important source of
sulfide generation in the gut [93]. Furthermore, a high
alcohol intake was also positively associated with UC (OR
2.42, 95 % CI 1.04–5.62), which may be relevant as sul-
fides are added to alcohol for both flavor and a preservative
[94]. A cross-sectional study in 81 patients with UC
reported a significant correlation (p \ 0.001) between
foods containing high levels of sulfite with higher sig-
moidoscopy scores, representative of more active disease
[95]. Clinical trials investigating whether a low-sulfur
intake may prevent relapse of UC are required. To the best
of our knowledge, there are no similar studies investigating
sulfur in CD, although work has reported interactions
between genetic polymorphisms and fat intake on CD
activity [96]. A high intake of total, saturated, and mono-
unsaturated fats, and a higher ratio of n-6/n-3 polyunsatu-
rated fatty acids with active disease are associated with a
more active disease phenotype, mainly in patients carrying
the variant alleles of TNF-alpha (857 C/T polymorphism)
and IL6 (174 G/C polymorphism). More clinical studies are
needed in both UC and CD investigating the effects of
many nutrients on relapse, remission and disease activity.
Air Pollution
Air pollution may plausibly increase the risk of relapse of
IBD through several mechanisms. Pollutants increase the
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secretion of TNF-a, which is elevated in healthy human
participants who inhaled diesel exhausts [97]. Furthermore,
animal studies suggested that air pollutants may damage
the colonic mucosa [98], and work in the respiratory sys-
tem showed an increased susceptibility to bacterial infec-
tion mediated by an impairment of the microbial defense
mechanism [99]. To date, only one study has investigated
air pollution and relapse rates of inflammatory bowel dis-
ease [100]. Here, an ecological investigation of IBD
patients in different counties in Wisconsin, USA (65 %
CD), compared the average total annual emission density
of air pollutants with IBD-related hospitalizations. This
reported that a 1-log increase in the density of total emis-
sion pollutants resulted in increased hospitalization for
both CD (IRR 1.39, 95 % CI 1.26–1.52) and UC alike (IRR
1.48, 95 % CI 1.27–1.73) [100]. Furthermore, hospital-
ization rates for the individual pollutants, such as carbon
monoxide, nitrous oxide, sulfur dioxide, volatile organic
chemicals and particulate matter \2.5 lm, were all
increased. To study the effects of pollutants, further ana-
lytical studies are required comparing exposure to pollu-
tants in the air between IBD patients with and without
relapse.
Conclusions
The mechanisms for disease relapses in CD and UC are
largely unknown, although probably involve a complex
interaction of immunological, environmental, pharmaco-
logical, psychological and dietary factors. To date, the
evidence strongly suggests that smoking adversely affects
CD and may alleviate UC. NSAIDs and estrogens may
aggravate the disease course, although the epidemiological
evidence is conflicting. Furthermore, antibiotics may have
a benefit in CD, but more studies investigating general and
specific antibiotics in different populations are required to
clarify further our understanding of the mechanisms
involved and what work needs to be done. Psychological
stress appears to precipitate IBD exacerbations. Work
investigating the effect of diet on relapse is in its infancy,
and it is preferable that diet is investigated in cohort
studies, including confirming whether sulfur may be
involved in UC. The effect of air pollutants is currently
limited, and possible links need to be investigated in eti-
ological studies. In the future, observational work is
required to clarify associations, as clinical trials of possible
exposures such as medications would be impossible due to
both ethical and pragmatic reasons. Observational studies
should investigate several aspects including the type of
disease; its site; detailed medication records, including
doses and durations; all known covariates (including
smoking and family history) and using controls who are
IBD patients in remission. Furthermore, many dietary
factors need to be studied and assessed for potential clinical
benefits in randomized controlled trials. Such work on
factors which affect relapse and recurrence may improve
patients’ quality of life through preventive measures.
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